secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001999480-26-000001
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience reports FY2025 net loss $63.2M; cash $177M; ALTO-207 Phase 2b on track for 1H 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents & restricted cash $177M as of Dec 31, 2025; runway into 2028 covers four key readouts.
- Net loss of $63.2M for FY2025 vs $61.4M in FY2024; R&D expenses $45.6M, G&A $20.7M.
- Acquired ALTO-207 (pramipexole/ondansetron) for TRD; Lancet-published PAX-D study showed Cohen's d=0.87 effect size.
- ALTO-207 Phase 2b trial expected to start 1H 2026, topline data 2H 2027; $50M PIPE completed in October 2025.
- ALTO-101 granted FDA Fast Track for CIAS; Phase 2 POC topline data expected around end of Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/0001999480-26-000001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/alto-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001999480-26-000001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer